<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>The Nevada National Board Professional Learning Institute | Sumner | Activity</title>
	<link>http://www.nationalboardinstitute.com/members/hopejute55/activity/</link>
	<atom:link href="http://www.nationalboardinstitute.com/members/hopejute55/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Sumner.</description>
	<lastBuildDate>Fri, 23 May 2025 17:06:54 -0700</lastBuildDate>
	<generator>https://buddypress.org/?v=9.1.1</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">e0c04eb7f9843f98506714372bc668ed</guid>
				<title>Sumner posted an update: Background Eflapegrastim, a novel, long-acting recombinant [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/42248/</link>
				<pubDate>Sun, 09 Feb 2025 08:35:22 -0800</pubDate>

									<content:encoded><![CDATA[<p>Background Eflapegrastim, a novel, long-acting recombinant human granulocyte-colony stimulating factor (rhG-CSF), consists of a rhG-CSF analog conjugated to a human IgG4 Fc fragment via a short polyethylene glycol linker. Preclinical and phase I and II pharmacodynamic and pharmacokinetic data showed increased potency for neutrophil counts for&hellip;<span class="activity-read-more" id="activity-read-more-42248"><a href="http://www.nationalboardinstitute.com/activity/p/42248/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">d66ca876ee134e19fe72e2b4b808e2e9</guid>
				<title>Sumner posted an update: Colibactin-producing E. coli (CoPEC) are frequently detected [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/41380/</link>
				<pubDate>Sat, 08 Feb 2025 08:39:18 -0800</pubDate>

									<content:encoded><![CDATA[<p>Colibactin-producing E. coli (CoPEC) are frequently detected in colorectal cancer (CRC) and exhibit procarcinogenic properties. Because increasing evidence show the role of immune environment and especially of antitumor T-cells in CRC development, we investigated the impact of CoPEC on these cells in human CRC and in the APCMin/+ mice colon.&hellip;<span class="activity-read-more" id="activity-read-more-41380"><a href="http://www.nationalboardinstitute.com/activity/p/41380/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">597c141ba24ec92ba0995cb6cc159a0d</guid>
				<title>Sumner posted an update: Deterministic sensitivity analysis indicated that these [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/35216/</link>
				<pubDate>Sat, 01 Feb 2025 08:42:34 -0800</pubDate>

									<content:encoded><![CDATA[<p>Deterministic sensitivity analysis indicated that these values were particularly sensitive to lung cancer prevalence, screening sensitivity and specificity, screening cost, and treatment costs for stage I and IV disease. From the probabilistic sensitivity analysis incremental cost-effectiveness ratios had a 98 % probability of being less then&hellip;<span class="activity-read-more" id="activity-read-more-35216"><a href="http://www.nationalboardinstitute.com/activity/p/35216/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">38a9caf6ef69ba7c82166957e5b39a96</guid>
				<title>Sumner posted an update: AIM The aims were to characterize pediatric medication [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/28251/</link>
				<pubDate>Tue, 28 Jan 2025 10:46:31 -0800</pubDate>

									<content:encoded><![CDATA[<p>AIM The aims were to characterize pediatric medication errors and to identify the prevalence of known high-alert substances in these errors. METHODS All pediatric drug-related incident reports and complaints nationally reported to the Health and Social Care Inspectorate in Sweden 2011-2017 regarding inpatients were characterized by context and&hellip;<span class="activity-read-more" id="activity-read-more-28251"><a href="http://www.nationalboardinstitute.com/activity/p/28251/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">9ea4a2d694ed940b8029cef9f674e721</guid>
				<title>Sumner became a registered member</title>
				<link>http://www.nationalboardinstitute.com/activity/p/28190/</link>
				<pubDate>Tue, 28 Jan 2025 10:38:51 -0800</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>